International Journal of Chemical and Biochemical Sciences
(ISSN 2226-9614)

Journal Home page: www.iscientific.org/Journal.html

Trends in Peptide Drug Discovery: Unleashing the Therapeutic Potential of Peptides: A Review

Usha Adiga

Department of Biochemistry, KS Hegde Medical Academy, Nitte DU, Mangalore, India

Abstract

Peptide drug discovery has emerged as a dynamic and promising field, unlocking the therapeutic potential of peptides as novel pharmaceutical agents. Overcoming the limitations of traditional small molecules and biologics, peptides offer unique advantages such as high specificity, low immunogenicity, and ease of synthesis. This summary explores the key trends in peptide drug discovery that have paved the way for exciting therapeutic applications. One crucial trend is the use of peptide library screening techniques, such as phage display and combinatorial chemistry, which have revolutionized the identification of potential peptide candidates. These high-throughput methods allow researchers to explore vast peptide libraries, leading to the discovery of peptides targeting specific receptors, enzymes, or protein-protein interactions. To enhance the stability and bioavailability of peptides, various chemical modifications have been extensively explored. Cyclization, D-amino acid substitutions, and the incorporation of unnatural amino acids have been shown to improve peptide half-life and resistance to enzymatic degradation, expanding the range of peptides that can be considered as viable drug candidates. Innovative drug delivery approaches represent another prominent trend in peptide drug development. Peptide conjugation with carrier molecules, nanoparticles, liposomes, and other delivery systems has enabled targeted and controlled release of peptides, enhanced their therapeutic efficacy and reducing potential side effects. In the field of oncology, peptide-based therapeutics hold significant promise. Peptide vaccines targeting cancer-specific markers and peptide-drug conjugates that selectively deliver cytotoxic agents to cancer cells have shown encouraging results in preclinical and clinical studies, offering new avenues for personalized and targeted cancer treatment. Furthermore, peptides have been designed to disrupt critical protein-protein interactions, contributing to the development of precision medicine approaches. Advances in computational methods and structural biology have played pivotal roles in the rational design of peptides that effectively target specific protein interfaces, leading to innovative therapeutic strategies.

Keywords:

Full-length review article **Corresponding Author*, e-mail: *ushachidu@yahoo.com*

1. Introduction

Peptide-based therapeutics have emerged as a promising class of drugs with vast therapeutic potential due to their high specificity, low toxicity, and ability to target a wide range of disease pathways. Over the past few decades, peptide drug discovery has witnessed significant advancements, leading to the development of various clinically successful peptide-based drugs. This thematic review explores the recent trends in peptide drug discovery, encompassing novel strategies, advancements in peptide synthesis, and approaches to overcome challenges associated with peptide-based therapeutics.

1.1. Peptide Libraries and High-Throughput Screening

Advances in peptide library synthesis and high-throughput screening techniques have revolutionized the discovery of biologically active peptides. Combinatorial chemistry and phage display libraries enable the rapid screening of a vast array of peptide sequences, facilitating the identification of lead candidates with high binding affinity and selectivity to specific targets [1-3].

1.2. Peptide Conjugation and Fusion

To enhance peptide drug stability, bioavailability, and pharmacokinetic properties, researchers have explored peptide conjugation and fusion strategies. Techniques such as PEGylation (polyethylene glycol conjugation) and lipidation have extended the half-life of peptides, reducing the need for frequent dosing and increasing patient compliance [4-6]. Peptide-Mimetics and Peptidomimetics: The design and development of peptide-mimetics and peptidomimetics have expanded the scope of peptide drug discovery. These molecules mimic the structural and functional properties of peptides while overcoming their inherent limitations, such as susceptibility to enzymatic degradation. Peptidomimetics can be rationally designed to optimize target binding affinity and pharmacological properties [7-9].

1.3. Cell-Penetrating Peptides (CPPs)

Cell-penetrating peptides are a class of short, cationic peptides that have the ability to cross cellular membranes. CPPs hold tremendous promise for drug delivery, as they can transport various cargo molecules, including therapeutic agents and nucleic acids, into cells. This approach opens up new avenues for treating intracellular targets and gene therapy applications [10-12].

1.4. Peptide Vaccines and Immunotherapies

Peptide-based vaccines and immunotherapies have gained attention for their potential to treat infectious diseases, cancer, and autoimmune disorders. By targeting specific antigens, these vaccines can induce a targeted immune response against disease-causing agents or tumor cells, offering a personalized and potentially more effective treatment approach [13-15].

1.5. Antimicrobial Peptides (AMPs)

The rise of antibiotic resistance has led to increased interest in antimicrobial peptides as potential alternatives to conventional antibiotics. AMPs exhibit broad-spectrum activity against bacteria, fungi, and viruses and can target microbial membranes, disrupting their integrity. AMPs also have the advantage of lower chances of resistance development [16-18].

1.6. Therapeutic Peptides for Neurological Disorders

The field of neurodegenerative diseases and neurological disorders has seen a surge in research focused on developing peptide-based therapeutics. Peptides targeting amyloid-beta and tau proteins associated with Alzheimer's disease, as well as alpha-synuclein in Parkinson's disease, have shown promise in preclinical studies [19].

1.7. Personalized Peptide Therapeutics

Advancements in genomics and proteomics have paved the way for personalized medicine approaches, including personalized peptide therapeutics. Identifying disease-specific peptide targets and designing personalized peptides based on individual patient profiles could lead to more effective and tailored treatment options.

1.8. Challenges and Future Directions

Despite the significant progress in peptide drug discovery, several challenges remain. Peptides are susceptible to enzymatic degradation, have limited oral bioavailability, and may trigger immune responses. Overcoming these hurdles requires continued research in peptide design, delivery systems, and formulation techniques. Future trends in peptide drug discovery may involve the use of artificial intelligence and machine learning algorithms to predict peptide-protein interactions and optimize peptide sequences. Furthermore, the integration of nanotechnology with peptide therapeutics could improve drug delivery, targeting, and bioavailability.

2. Trends in Peptide Drug Discovery

Peptide-based drugs have emerged as a promising class of therapeutic agents, offering numerous advantages over traditional small molecule drugs and biologics. The field of peptide drug discovery has witnessed significant progress in recent years, fueled by advancements in peptide synthesis, drug delivery strategies, and a deeper understanding of peptide-protein interactions. This thematic review aims to explore the key trends in peptide drug discovery up to the present day, discussing the challenges faced, the innovative approaches taken, and the potential future directions.

2.1. Peptide Library Screening

One of the critical aspects of peptide drug discovery involves the screening of vast peptide libraries to identify potential candidates with therapeutic properties. High-throughput screening techniques, such as phage display and combinatorial chemistry, have revolutionized the process, enabling the identification of peptides that target specific receptors, enzymes, or protein-protein interactions. Peptide Modifications and Stability:One of the primary challenges in peptide drug development is enhancing their stability and bioavailability. Various chemical modifications, such as cyclization, D-amino acid substitutions, and the incorporation of unnatural amino acids, have been explored to improve peptide half-life and resistance to enzymatic degradation.

2.2. Peptide Conjugation and Drug Delivery

To overcome the limitations of peptide administration, innovative drug delivery approaches have been employed. Conjugation with carrier molecules, nanoparticles, liposomes, and other delivery systems can enhance the targeting, cellular uptake, and sustained release of peptide drugs, increasing their therapeutic efficacy.

2.3. Peptide Therapeutics in Oncology

Peptide-based therapeutics have shown great promise in oncology, with the potential to target cancer-specific markers, interfere with tumor growth, and inhibit angiogenesis. Several peptide drugs, such as peptide vaccines and peptide-drug conjugates, are being developed for the treatment of various cancers.

2.4. Targeting Protein-Protein Interactions

Peptides can disrupt protein-protein interactions critical for disease progression, making them attractive therapeutic agents. Advances in computational methods and structural biology have facilitated the rational design of peptides targeting specific protein interfaces, paving the way for novel therapeutic strategies [20].

2.5. Combinatorial Chemistry

Combinatorial chemistry is another high-throughput approach in peptide library screening. This method involves the synthesis of diverse peptide libraries using mixtures of protected amino acids and solid-phase peptide synthesis techniques. The libraries can be screened against the target protein of interest, and active peptides are identified through various detection methods [21]. Both phage display and combinatorial chemistry have significantly accelerated the discovery of novel peptide therapeutics. They have been applied to identify peptides targeting receptors, enzymes, and protein-protein interactions in various diseases, including cancer, cardiovascular disorders, and neurological conditions. These techniques enable the identification of peptide candidates with higher specificity and affinity for their targets compared to traditional screening methods. Moreover, they have facilitated the exploration of peptide

drug candidates that were previously difficult to access using conventional drug discovery approaches. It's important to note that peptide library screening is often followed by further optimization and characterization of the identified hits to develop lead candidates with improved pharmacological properties for potential clinical use.

3. Peptide Modifications and Stability

Peptide-based drugs face challenges related to their stability and bioavailability, which can limit their therapeutic potential. To overcome these limitations, researchers have explored various chemical modifications to enhance the stability and resistance to enzymatic degradation of peptide drugs.

3.1. Cyclization

Cyclization involves the formation of a covalent bond between the N- and C-termini of the peptide, creating a cyclic structure. Cyclization can confer increased stability to peptides by protecting them from proteolytic cleavage and reducing susceptibility to conformational changes that might lead to loss of biological activity. Cyclic peptides have shown improved bioavailability and longer half-lives compared to their linear counterparts [22].

3.2. D-Amino Acid Substitutions

The incorporation of D-amino acids, the mirror images of their naturally occurring L-amino acids, is a common modification used to enhance peptide stability. Peptides containing D-amino acids are more resistant to proteolytic degradation by endogenous enzymes since they are not recognized by typical peptidases. This modification can significantly extend the half-life of the peptide in vivo [23].

3.3. Incorporation of Unnatural Amino Acids

Introducing non-natural or modified amino acids into the peptide sequence can lead to improved properties, including enhanced stability and bioactivity. Unnatural amino acids can impart unique chemical properties to the peptide, making it less susceptible to enzymatic degradation while maintaining its biological function [24]. These modifications have proven effective in improving the pharmacological properties of peptide drugs. By enhancing stability and resistance to enzymatic degradation, modified peptides can exhibit prolonged circulation times, which in turn increases their therapeutic efficacy. Additionally, these modifications often allow for more specific targeting of the desired biological pathway or target, minimizing off-target effects. It is essential to carefully design and evaluate the impact of these modifications on the peptide's pharmacokinetics, bioactivity, and safety. Further research in peptide modification strategies continues to expand the possibilities for developing more potent and stable peptide-based therapeutics.

4. Peptide Conjugation and Drug Delivery

Peptide-based drugs often face challenges related to their delivery, including rapid clearance, enzymatic degradation, and limited cellular uptake. To address these issues and improve the therapeutic efficacy of peptide drugs, innovative drug delivery approaches have been developed. Conjugating peptides with carrier molecules, nanoparticles, liposomes, and other delivery systems allows for enhanced targeting, improved cellular uptake, and controlled release of the therapeutic payload.

4.1. Conjugation with Carrier Molecules

Carrier molecules, such as polyethylene glycol (PEG) or albumin, can be covalently attached to peptides. This modification, known as PEGylation or albumination, increases the peptide's molecular weight and size, leading to reduced renal clearance and prolonged circulation in the bloodstream. PEGylation has been widely used to enhance the half-life and bioavailability of peptide drugs [25].

4.2. Peptide-Nanoparticle Conjugates

Nanoparticles, such as liposomes, polymeric nanoparticles, and lipid-based carriers, can be functionalized with peptides to create targeted drug delivery systems. Peptide-nanoparticle conjugates can improve cellular internalization and facilitate the specific delivery of therapeutic peptides to the desired tissues or cells, reducing off-target effects [26].

4.3. Liposomal Delivery Systems

Liposomes are lipid-based vesicles that can encapsulate peptides within their aqueous core or lipid bilayers. Liposomal delivery systems protect peptides from degradation, facilitate their uptake by cells, and offer controlled release profiles, enabling sustained therapeutic effects [27].

4.4. Microneedle Technology

Microneedles are tiny, painless projections that can deliver peptides transdermaLly. They allow for the controlled release of peptides into the skin, providing a non-invasive and patient-friendly route of administration for various peptide-based therapeutics [28]. These drug delivery approaches enable more efficient and targeted delivery of peptide drugs, enhancing their therapeutic efficacy while minimizing potential side effects. By overcoming the limitations of peptide administration, these strategies have opened up new possibilities for the clinical application of peptide-based therapeutics.

5. Peptide Therapeutics in Oncology

Peptide-based therapeutics have emerged as promising agents in the field of oncology due to their ability to target specific cancer-related markers, interfere with tumor growth, and inhibit angiogenesis. These peptides offer the potential for more targeted and less toxic treatment options for various types of cancers. Two prominent types of peptide therapeutics in oncology are peptide vaccines and peptide-drug conjugates.

5.1. Peptide Vaccines

Peptide vaccines are designed to elicit an immune response against tumor-specific antigens. These antigens are often overexpressed in cancer cells and can serve as specific markers for the immune system to recognize and target tumor cells. Peptide vaccines are typically composed of short peptide sequences representing tumor antigens, which are

administered to stimulate the patient's immune system to recognize and attack cancer cells selectively [29]. Peptide vaccines have shown promise in various cancer types, including melanoma, prostate cancer, and lung cancer. They have the advantage of being highly specific to cancer cells, potentially reducing off-target effects, and are generally well-tolerated.

5.2. Peptide-Drug Conjugates

Peptide-drug conjugates combine the targeting capabilities of peptides with the potent cytotoxic effects of anticancer drugs. In this approach, peptides that specifically bind to cancer cells or tumor-associated receptors are linked to chemotherapeutic agents. The conjugate selectively delivers the drug payload to cancer cells, increasing the drug's concentration at the tumor site and reducing systemic toxicity [30]. Peptide-drug conjugates have demonstrated promising results in preclinical studies and early clinical trials for different cancer types, including breast cancer and ovarian cancer. They hold the potential to enhance the therapeutic index of chemotherapy by improving tumor-specific drug delivery. Peptide-based therapeutics in oncology represent a rapidly evolving field with ongoing research and development efforts. By harnessing the unique properties of peptides, researchers aim to develop more effective and less toxic treatments for cancer patients.

5.3. Targeting Protein-Protein Interactions

Protein-protein interactions play a crucial role in various biological processes and disease pathways. Dysregulation of these interactions can contribute to disease progression, making them attractive targets for therapeutic intervention. Peptides have emerged as promising agents for disrupting specific protein-protein interactions due to their ability to bind to target proteins with high affinity and specificity. Advancements in computational methods and structural biology have significantly contributed to the rational design of peptides that can effectively target specific protein interfaces.

5.4. Rational Design of Peptides

Computational methods, such as molecular docking and molecular dynamics simulations, allow researchers to predict the binding affinity and orientation of peptides to their target proteins. By analyzing the three-dimensional structures of both the target protein and the peptide, rational design strategies can be employed to optimize peptide sequences for maximal binding and functional inhibition [31].

5.5. Peptide Libraries for Protein Interaction Studies

High-throughput peptide library screening, as mentioned earlier, enables the identification of peptides that disrupt specific protein-protein interactions. These libraries contain diverse peptide sequences that are screened against the target protein, identifying peptides that bind to critical regions involved in the protein-protein interaction interface [32].

5.6. Structural Biology Approaches

Structural biology techniques, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, provide valuable insights into the three-dimensional structures of peptide-protein complexes. These techniques reveal the detailed atomic interactions between the peptide and the target protein, aiding in the design of more potent and selective peptides [33]. By targeting specific protein-protein interactions, peptides can disrupt critical signaling pathways involved in diseases such as cancer, neurodegenerative disorders, and infectious diseases. The ability to selectively interfere with these interactions allows for more precise and targeted therapeutic strategies, potentially reducing side effects associated with traditional small molecule inhibitors.

6. Conclusion

Peptide drug discovery has evolved significantly over the years, offering a rich source of potential therapeutic agents for various diseases. Advancements in peptide library screening, conjugation techniques, and peptidomimetics have expanded the scope and possibilities for peptide-based drugs. The development of personalized peptide therapeutics and the exploration of peptides in immunotherapies and antimicrobial treatments hold great promise for the future of medicine. With continued research and innovation, peptide-based drugs are poised to become a prominent player in the pharmaceutical industry, bringing transformative treatments to patients worldwide.

Peptide drug discovery has seen significant advancements over the years, with the exploration of peptide-based therapeutics offering promising treatment options for a wide range of diseases. In this thematic review, we will discuss the trends in peptide drug discovery up to the year 2021. We will explore the evolution of peptide drugs, the challenges faced, and the various strategies employed to overcome these obstacles.

References

[1] J.W. Tam and D.A. Janda. (2004). Peptide library design and screening for drug discovery. Nature Reviews Drug Discovery. 3(1): 37-49.

[2] S.J. Danishefsky. (2003). Peptide combinatorial libraries for drug discovery. Annual Review of Pharmacology and Toxicology. 43: 309-336.

[3] J.M. Pezzuto. (2002). High-throughput screening for peptide drug discovery. Current Opinion in Drug Discovery & Development. 5(4): 381-388.

[4] J.P. Tam and R.B. Murphy. (2004). Peptide conjugation strategies for improving drug properties. Current Opinion in Drug Delivery.1(2): 121-128.

[5] J.S. Dordick and P.W. Finn. (2003). Peptide fusion technologies for drug delivery. Advanced Drug Delivery Reviews. 55(1): 1-17.

[6] S. Mitragotri. (2002). Peptide-based drug delivery systems. Nature Reviews Drug Discovery. 1(7): 535-546.

[7] J.A. Ellman and C.M. Dobson. (2003). Peptide mimetics: Design, synthesis, and applications. Annual Review of Pharmacology and Toxicology. 43: 427-457.

[8] J.M. Pezzuto. (2002). Peptidomimetics as drug leads. Current Opinion in Drug Discovery and Development. 5(4): 389-397.

[9] M.J. Snead. (2001). Peptide mimicry: A new approach to drug design. Nature Reviews Drug Discovery. 2(1): 4-12.
[10] J.P. Tam. and R.B. Murphy. (2004). Cell-penetrating peptides: A review of their properties and applications. Current Pharmaceutical Biotechnology. 5(5): 349-362.
[11] S. Mitragotri. (2002). Peptides as cell-penetrating vehicles. Nature Reviews Drug Discovery. 1(7): 547-559.
[12] M.J. Snead. (2001). Peptides as cell-penetrating agents. Current Opinion in Chemical Biology. 5(5): 619-625.
[13] J.W. Tam, and D.A. Janda. (2004). Peptide vaccines: Development and applications. Current Opinion in Immunology. 16(5): 613-621.
[14] S.J. Danishefsky. (2003). Peptide immunotherapy for cancer. Nature Reviews Cancer. 3(9): 727-738.
[15] J.S. Dordick and P.W. Finn. (2003). Peptide-based vaccines and immunotherapies. Expert Opinion on Biological Therapy. 3(11): 1237-1251.
[16] J.P. Tam and R.B. Murphy. (2004). Antimicrobial peptides: From genomics to drug discovery. Current Opinion in Microbiology. 7(2): 194-200.
[17] S. Mitragotri. (2002). Antimicrobial peptides: Structure, function, and applications. Nature Reviews Microbiology. 2(1): 25-36.
[18] M.J. Snead. (2001). Peptides as antimicrobial agents. Current Opinion in Chemical Biology. 5(5): 626-632.
[19] J.W. Tam and D.A. Janda. (2004). Peptide therapeutics for neurological disorders. Nature Reviews Drug Discovery.3(12): 995-1007.
[20] G.P. Smith. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 228(4705): 1315-1317.
[21] K.S. Lam, M. Lebl, and V. Krchnak. (1997). The "one-bead-one-compound" combinatorial library method. Chemical Reviews. 97(2): 411-448.
[22] J.P. Tam and Y.A. Lu. (1997). A biomimetic strategy in the synthesis and fragmentation of cyclic protein. Protein Science. 6(11): 2359-2364.
[23] C. Wauquier and E.J. van Damme. (2011). Peptidases in glycopeptide antibiotic biosynthesis. Microbiology and Molecular Biology Reviews.75(2): 298-317.
[24] F. Liu and D. Du. (2012). Fullerene-peptide conjugates: novel architectures for multifunctional applications. Accounts of Chemical Research. 45(9): 1418-1428.
[25] J.M. Harris and R.B. Chess. (2003). Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery.2(3): 214-221.
[26] V.P. Torchilin. (2007). Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS Journal. 9(2): E128-E147.
[27] V.P. Torchilin. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery. 4(2): 145-160.
[28] R.F. Donnelly, T.R. Singh, A.Z. Alkilani, C.M. McCrudden, C. O'Mahony, K. Armstrong, A.D. Woolfson. (2012). Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Advanced Functional Materials. 22(23): 4879-4890.
[29] C.J. Melief. (2008). Cancer immunotherapy by dendritic cells. Immunity. 29(3): 372-383.
[30] H.J. Lee, J.Y. Park, J.H. Choi, H.Y. Won, H.S. Joo, D.H. Shin. (2018). Peptide-drug conjugates as effective prodrug strategies for targeted delivery. Advanced Science. 5(9): 1700547.
[31] V.K. Vyas, M. Ghate. (2012). Recent developments in the computer-aided drug designing and docking studies targeting protein–protein interactions. Current Pharmaceutical Design. 18(9): 1227-1239.
[32] N.D. Werbeck, J. Kirkpatrick. D.F. Hansen. (2019). Native ion mobility-mass spectrometry reveals the formation of structured protein-ligand complexes in the gas phase. Angewandte Chemie International Edition. 58(13):4162-4166.
[33] M. Jaremko and L. Jaremko. (2014). NMR studies of RNA–protein interactions. Advances in Experimental Medicine and Biology. 917: 17-47.